VJOncology is committed to improving our service to you

ESMO 2018 | MEK inhibitors for melanoma: new combination approved

VJOncology is committed to improving our service to you

Paolo Ascierto

MEK pathway inhibitors have been essential in the treatment of melanoma, and recently a new MEK inhibitor combination was approved by the FDA. Here, Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy, discusses the three MEK inhibitor combinations currently approved for the treatment of melenoma. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter